A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

Completed · Phase 3

Conditions studied: Hypertension, Diabetes

In brief

To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide

Key facts

Study ID

NCT00219102

Run by

Novartis

People needed

336

Starts

2005-06-01

Expected to finish

2007-05-01

Last updated by the study team

2020-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with essential hypertension
• Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.
• Patients who are eligible and able to participate in the study

You may not qualify if…

• Severe hypertension
• Uncontrolled diabetes type I and II
• History or evidence of a secondary form of hypertension
• History of Hypertensive encephalopathy or cerebrovascular accident.
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Investigative Site — Salisbury, North Carolina, United States
• Investigative Site — Kortrijk, Belgium
• Investigative Site — Bucharest, Romania
• Investigative Site — Madrid, Spain
• Investigative Site — Stockholm, Sweden
• Novartis Pharmaceuticals — Basel, Switzerland
• Investigative Site — Kiev, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.